期刊文献+

脂康颗粒与辛伐他汀降脂治疗随机对照研究 被引量:2

Randomized Comparative Study on the Lipid Lowering Effects of Zhikang Granule and Simvastatin
下载PDF
导出
摘要 目的对中药降脂制剂脂康颗粒与辛伐他汀在降脂治疗中的作用。方法门诊筛选符合入选标准的原发性血脂异常的患者,按照2:1的比例随机分为脂康颗粒组30例,辛伐他汀组15例。观察24周治疗期间两组的血脂达标率,对高敏C-反应蛋白(high sensitivity C reactive protein,hs-CRP)水平的影响,并进行安全性评价。结果治疗结束时,不同时间点(4、8、12、24周)总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(lowdensity lipoprotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(high density lipoprotein choles-terol,HDL-C)和甘油三酯(triglyceride,TG)水平两组间比较,差异均无统计学意义(P>0.05);脂康颗粒组:4、8、12、24周TC、LDL-C水平与治疗前比较明显降低(P<0.01);TG、HDL-C水平治疗前后差异无统计学意义(P>0.05);辛伐他汀组:4、8、12、24周TC、LDL-C水平与比较明显降低(P<0.01),HDL-C(P=0.02);TG水平差异无统计学意义(P>0.05)。LDL-C和TC达标,脂康颗粒组与辛伐他汀组4周比较,分别为26例(86.7%)与15例(100%),24例(80%)与15例(100%);24周16例(53.3%)与9例(60.0%),27例(90.0%)与14例(93.3%),差异无统计学意义(P>0.05);转氨酶、血肌酐、血尿酸水平、hs-CRP,差异均无统计学意义(P>0.05)。结论脂康颗粒具有确切的降低TC和LDL-C的作用,较长期应用安全可靠。 Objective To compare the lipid lowering effects of Zhikang Granule(ZKG)and simvastatin.Methods Forty-five out-patients with hyperlipemia who met the entry criteria were enrolled and randomized into two groups in the ratio of 2∶1,30 patients in the ZKG group and 15 patients in the simvastatin group.The lipid lowering effects and safety of treatment during the 24-week therapeutic period,as well as the influence of treatment on plasma high sensitivity C reactive protein(hs-CRP)level in patients were observed.Results No significant difference between the two groups was observed in serum levels of total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein-cholesterol(HDL-C)and triglyceride(TG)at the 4th,8th,12th and 24th week(P0.05).However,as compared with baseline,significant reduction of TC and LDL-C in both groups was shown at all the observing time points(P0.01),while the changes in TG and HDL-C were insignificant(P0.05).The control rates of LDL-C and TC in the ZKG group and the simvastatin group were 86.7%(26/30)versus 100%(15/15)at the 4th week,80.0%(24/30)versus 100%(15/15)at the 8th week,53.3%(16/30)versus 60.0%(9/15)at the 12th week,and 90.0%(27/30)versus 93.3%(14/15)at the 24th week,respectively,all showed insignificant difference between groups.No statistical differences were found between groups in levels of plasma transaminase,creatinine,uric acid and hs-CRP(P0.05).Conclusion ZKG has a definite effect in lowering LDL-C and TC,and it is safe in long-term administration.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2010年第10期1052-1055,共4页 Chinese Journal of Integrated Traditional and Western Medicine
关键词 脂康颗粒 辛伐他汀 达标率 安全性 Zhikang Granule simvastatin control rate safety
  • 相关文献

参考文献7

  • 1Tani S,Nagao K,Anazawa T,et al.Coronary plaque regression and lifestyle modification in patients treated with pravastatin.-Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol[J].Circ J,2010,74(5):954-961.
  • 2Takayama T,Hiro T,Yamagishi M,et al.Effect of rosuvastatin on coronary atheroma in stable coronary artery disease:multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects(COSMOS)[J].Circ J,2009,73(11):2110-2117.
  • 3Nasu K,Tsuchikane E,Katoh O,et al.Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound[J].JACC Cardiovasc Interv,2009,2(7):689-696.
  • 4Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults.Evaluation and treatment of high blood cholesterol in adults:Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection,evaluation and treatment of high blood cholesterol in adults(Adults Treatment Panel Ⅲ)[J].JAMA,2001,285(19):2486-2497.
  • 5田相同,姜良花,王明杰.脂康颗粒调节血脂异常的临床研究[J].中西医结合心脑血管病杂志,2006,4(2):121-122. 被引量:2
  • 6Ridker PM,Rifai N,Lowenthal SP.Rapid reduction in Creactive protein with cerivastatin among 785 patients with primary hypercholesterolemia[J].Circulation,2001,103(9):1191-1193.
  • 7Dale KM,White CM,Henyan NN,et al.Impact of statin dosing intensity on transaminase and creatine kinase[J].Am J Med,2007,120(8):706-712.

二级参考文献3

  • 1中华人民共和国卫生部.中药新药治疗高脂血症的临床研究指导原则[M].北京:人民卫生出版社,1993.28.
  • 2方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 3马云山,刘志伟,王志军,赵从军,宋承山.康脂胶囊治疗高脂血症的临床观察[J].山东中医杂志,1998,17(7):297-298. 被引量:5

共引文献1

同被引文献25

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部